Biocon Biologics completes integration of Viatris Biosimilars’ business in North America
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Sarah currently serves as the Chief Financial Officer and Principal Accounting Officer for Criteo S.A.
This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
This approval has come from the company's finished dosage form manufacturing facility
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Subscribe To Our Newsletter & Stay Updated